Literature DB >> 30591493

PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer.

Hiroaki Saito1, Shota Shimizu2, Yusuke Kono2, Yuki Murakami2, Yuji Shishido2, Kozo Miyatani2, Tomoyuki Matsunaga2, Yoji Fukumoto2, Keigo Ashida2, Yoshiyuki Fujiwara2.   

Abstract

BACKGROUND: Programmed death-1 (PD1) is an immunoinhibitory receptor, and PD1 overexpression on T-cells is involved in immune evasion in cancer. This study investigated the prognostic significance of PD1 expression on T-cells in gastric cancer.
MATERIALS AND METHODS: PD1 expression on CD4+ and CD8+ T-cells obtained from peripheral blood mononuclear cells was evaluated by multicolor flow cytometry.
RESULTS: Based on cutoff values from receiver operating characteristic analysis, patients were sub-grouped according to PD1 positivity as having high or low PD1+CD4+ T-cell (cutoff ≥34.2%) and PD1+CD8+ T-cell (cutoff ≥28.7%) frequencies. Five-year overall survival rates differed significantly between the groups with low and high frequency of PD1+CD4+ T-cells (75.1% vs. 27.2%, respectively; p=0.0008). The 5-year overall survival rates were 78.3% and 37.2%, respectively, for the corresponding PD1+CD8+ T-cell subgroups (p=0.0004). Multivariate analysis revealed that the frequency of PD1+CD8+ T-cells was an independent prognostic indicator.
CONCLUSION: The frequency of PD1+CD8+ T-cells may predict the prognosis of patients with gastric cancer. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; PD-L1; PD1; T-cells; prognosis

Mesh:

Substances:

Year:  2019        PMID: 30591493     DOI: 10.21873/anticanres.13132

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

Review 2.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

3.  Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.

Authors:  Bor-Chyuan Su; Chen-Hung Ting; Kang-Yun Lee; Sheng-Ming Wu; Po-Hao Feng; Yao-Fei Chan; Jyh-Yih Chen
Journal:  Histol Histopathol       Date:  2020-10-28       Impact factor: 2.303

4.  Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch.

Authors:  Wen Juan Tu; Robert D McCuaig; Abel H Y Tan; Kristine Hardy; Nabila Seddiki; Sayed Ali; Jane E Dahlstrom; Elaine G Bean; Jenny Dunn; Jade Forwood; Sofia Tsimbalyuk; Kate Smith; Desmond Yip; Laeeq Malik; Thiru Prasanna; Peter Milburn; Sudha Rao
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

5.  Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.

Authors:  Luka Brcic; Thomas Klikovits; Zsolt Megyesfalvi; Berta Mosleh; Katharina Sinn; Richard Hritcu; Viktoria Laszlo; Tanja Cufer; Ales Rozman; Izidor Kern; Katja Mohorcic; Marko Jakopovic; Miroslav Samarzija; Sven Seiwerth; Vitezslav Kolek; Ondřej Fischer; Petr Jakubec; Jozef Škarda; Balazs Gieszer; Balazs Hegedus; Janos Fillinger; Ferenc Renyi-Vamos; Anna Buder; Agnes Bilecz; Walter Berger; Michael Grusch; Konrad Hoetzenecker; Walter Klepetko; Mir Alireza Hoda; Martin Filipits; Balazs Dome
Journal:  Transl Lung Cancer Res       Date:  2021-04

6.  Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8+ T cell cytotoxicity in patients with gastric cancer.

Authors:  Junli Xu; Rongya Guo; Jing Jia; Yun He; Shuixiang He
Journal:  BMC Immunol       Date:  2021-10-07       Impact factor: 3.615

Review 7.  Checkpoint inhibitor/interleukin-based combination therapy of cancer.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Cancer Med       Date:  2022-03-17       Impact factor: 4.711

Review 8.  Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis.

Authors:  Jacek Baj; Karolina Brzozowska; Alicja Forma; Amr Maani; Elżbieta Sitarz; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2020-04-06       Impact factor: 5.923

9.  Contribution of Leishmania braziliensis antigen-specific CD4+ T, CD8+ T, NK and CD3+CD56+NKT cells in the immunopathogenesis of cutaneous leishmaniasis patients: Cytotoxic, activation and exhaustion profiles.

Authors:  Clarissa F Cunha; Raquel Ferraz-Nogueira; Vanessa F A Costa; Maria Inês F Pimentel; Thaize Q Chometon; Marcelo R Lyra; Armando O Schubach; Alda Maria Da-Cruz; Alvaro Luiz Bertho
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

10.  PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer.

Authors:  Yang Shen; Yongsheng Teng; Yipin Lv; Yongliang Zhao; Yuan Qiu; Weisan Chen; Lina Wang; Ying Wang; Fangyuan Mao; Ping Cheng; Daiyuan Ma; Yuan Zhuang; Quanming Zou; Liusheng Peng
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.